Company of the week: Innovo Therapeutics
Innovo Therapeutics Inc. is a Seoul-based private biotechnology company developing small-molecule therapeutics across inflammatory immune disease, fibrosis, and oncology.
Discovery and lead optimisation are conducted on a proprietary AI-augmented computational platform branded DeepZema®.
The company was founded in 2019 by Hee-Dong Park, a former LG Chem drug-discovery executive, and operates an R&D centre in Daejeon alongside its Mapo-gu headquarters in Seoul.
It is privately held, has raised approximately $33.9M in equity to date per PitchBook, and has been a recurring grantee of the Korea Drug Development Fund (KDDF) across multiple programmes.
On the surface, Innovo is a conventional Korean small-molecule platform biotech: ten preclinical-to-Phase 2 programmes, two assets in or past Phase 1/2 (INV-001 for hypertrophic scars and INV-101 for ulcerative colitis), and a steady cadence of KDDF-funded lead-development projects.
Read the licensing ledger and the IP footprint as of today, May 13, 2026, and a more specific story emerges.
On May 12, 2026, Daewoong Pharmaceutical filed a Korea Exchange disclosure announcing a licensing agreement with Innovo covering INV-008, a preclinical oral 15-PGDH inhibitor for inflammatory bowel disease.
Both companies followed with a joint press release on May 13.
The disclosed economics, with the detailed milestone breakdown sourced from 약사공론's reporting on the Korea Exchange filing:
| Layer | Amount (KRW) | Approx USD | Trigger |
|---|---|---|---|
| Upfront (non-refundable) | 6.5 billion | ~$4.4M | Signing |
| Development milestones | up to 19.0 billion | ~$12.8M | Clinical progression |
| Regulatory milestones | up to 207.0 billion | ~$139M | Approvals |
| Sales milestones | up to 430.0 billion | ~$289M | Commercial thresholds |
| Total | up to 662.5 billion | ~$445M |
Daewoong takes exclusive worldwide development, manufacturing and commercialisation rights for IBD and other indications, with the two companies operating a joint development model.
Running royalty terms have not been publicly disclosed.
For a private Korean preclinical asset that has not yet entered the clinic, a $4.4M / $441M structure on worldwide exclusive rights is a meaningful headline.
For royalty market analysts, the more interesting question is how the asset, the broader pipeline, and the underlying discovery platform compare to the global AI-drug-discovery cohort whose royalty-financeable templates are being established right now.
This article examines Innovo's origins, the DeepZema® platform and its positioning relative to peer AI-drug-discovery companies as of May 2026, the full pipeline through W19 2026, the INV-008 royalty stack mechanics, the prior Phase 2 INV-001 scar programme, the unpartnered INV-101 Phase 2 IBD programme, the broader IP footprint, and the asset-by-asset royalty potential.
Origins: An LG Chem spinout building a different kind of AI platform
Innovo Therapeutics was incorporated in 2019.
The founding team is anchored by CEO Hee-Dong Park, who previously held senior drug-discovery roles at LG Chem before launching the company with a small-molecule focus across inflammation, fibrosis, and oncology.
Korean press coverage of the May 13 Daewoong announcement explicitly flags the LG Chem lineage and the company's transition from Atinum and Mirae Asset venture capital to Daewoong as a strategic licensee.
The KDDF relationship runs across multiple programmes.
INV-008 has been KDDF-supported since June 2023 through the National New Drug Development Project, jointly funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare.
INV-005 (IPF) and INV-006 (androgenic alopecia) have both received two-year KDDF lead-development grants per Innovo's pipeline page.
INV-101 received KDDF support for its Phase 1 trial in the United States and has been earmarked for a further two years of KDDF support.
KDDF support matters for royalty analysis for two reasons.
First, KDDF grants in Korea are structured as non-dilutive cost reimbursement with no royalty pull-through on commercialised products, leaving the cap table and downstream royalty stack clean.
Second, KDDF support functions as a credibility signal for downstream Korean licensees (Daewoong, Yuhan, Hanmi, SK Biopharmaceuticals) and increasingly for global pharma in-licensing teams scouting Korean origination.
The company is privately held.
PitchBook attributes cumulative ~$33.9M of equity across multiple rounds, with Axis Investment, Company K Partners, IMM Investment, Tigris Investment, and Timefolio Capital listed among institutional backers.
Korean press additionally names Atinum Investment and Mirae Asset Venture Investment on the cap table.
DeepZema® and the AI Drug Discovery Landscape (May 2026)
The most interesting strategic positioning at Innovo is buried in plain sight on its technology page, where the company explicitly contrasts its approach to that of the better-known AI-drug-discovery cohort.
The relevant passage from Innovo's own description:
"The common features of AI-based technologies at these companies [referring to Insilico Medicine and Exscientia] appear to be (1) the omics-based identification of disease-related targets and (2) the multi-parameter lead optimization using generative models. While these approaches will certainly help the discovery process, they tend to demand some extent of financial and human resources that small start-ups cannot afford. Thus, Innovo Therapeutics adopted a more practical approach to address this issue by augmenting artificial intelligence to existing computational drug discovery technologies."
DeepZema® is positioned not as a generative-chemistry-first platform but as a practical AI-augmented computational chemistry stack.
The component layers include ML-based target identification, ML-based ADME/toxicity prediction, traditional de novo design methods to generate analogues that feed into docking, deep-learning scoring functions for binding-pose evaluation, and developability assessment modules covering solubility, permeability, and formulation.
The platform is delivered via a web interface designed for "simplicity, democratism, and practicality," with kinome profiling, target prediction, and ADME/toxicity prediction as core application modules.
The technical claim is materially different from the generative-AI-first positioning at the better-known AI-drug-discovery peers.
The peer landscape has shifted meaningfully over the past 18 months and looks different in May 2026 than it did in early 2024.
To frame the comparison cleanly:
| Company | Platform approach | Most advanced asset | Stage as of May 2026 | Clinical PoC |
|---|---|---|---|---|
| Insilico Medicine | End-to-end generative AI (Pharma.AI: PandaOmics target ID + Chemistry42 generative chemistry + InClinico trial design) | Rentosertib (ISM001-055, TNIK inhibitor, IPF) | Phase 2a complete; Phase 2b enrolling; inhaled formulation IND cleared April 28, 2026 (13th IND clearance from the pipeline) | Yes — Nature Medicine June 2025: +98.4 mL FVC vs −20.3 mL placebo at 60 mg QD; first peer-reviewed Phase 2a proof-of-concept for a fully AI-generated drug |
| Recursion (post-Exscientia merger, closed November 20, 2024) | Phenomics imaging at scale + Recursion OS + Exscientia precision chemistry | REC-4881 (MEK1/2 inhibitor, FAP) is now lead Phase 2 asset after REC-3964 C. diff programme was halted in May 2025 | Q1 2026 update: REC-4881 strong Phase 2 efficacy in FAP (43% median polyp burden reduction, n=6, week 13); FDA registrational engagement initiated; REC-1245 (RBM39) Phase 1 ongoing; REC-3565 (MALT1) Phase 1 ongoing; REC-4539 (LSD1) first patient dosed Q1 2026 | Phase 2 signal on REC-4881 in FAP; no Phase 2 PoC publication yet |
| Schrödinger | Physics-based molecular simulation + ML; software licensing + proprietary therapeutics; agentic AI co-scientist (Bunsen) launching summer 2026 | Zasocitinib (TAK-279, TYK2 inhibitor) via Takeda partnership — currently the most clinically advanced AI-assisted drug globally | Phase 3; originated at Nimbus, acquired by BMS for $6B, now in Takeda's Phase 3 development; Q1 2026 revenue $58.6M ($35.6M software + $22.9M drug discovery); $406M cash; 15 royalty-eligible partner programmes with ~$5B in potential milestone payments | Pipeline-wide; Eli Lilly's $2.3B April 2026 acquisition of Ajax Therapeutics (Schrödinger 6% equity holder) is the latest validation |
| Relay Therapeutics | Protein motion dynamics + computational chemistry (Dynamo platform) | RLY-2608 (PI3Kα), RLY-1971 (SHP2, partnered with Genentech) | Multiple clinical-stage | Some clinical signal, no Phase 2 PoC publication yet |
| BenevolentAI | Knowledge-graph target ID + ML | Multiple early-stage | Delisted from Euronext Amsterdam March 13, 2025 via merger with Osaka Holdings S.à r.l.; private company; significant restructuring 2024-2025; runway extended into 2027 via workforce reduction | No |
| Innovo Therapeutics (DeepZema®) | AI-augmented traditional comp chem (ML target ID + ML ADME + classical de novo design + DL scoring) | INV-008 (15-PGDH, IBD, licensed to Daewoong May 2026); INV-101 (PYGL, UC, Phase 2 ready) | INV-008 preclinical; INV-101 Phase 2 ready; INV-001 Phase 3 IND submitted | Not yet |
A few observations relevant to the royalty market and to how Innovo should be benchmarked:
Schrödinger holds the most clinically advanced AI-assisted asset globally as of May 2026.
Zasocitinib (TAK-279), the TYK2 inhibitor originally designed at Nimbus Therapeutics using Schrödinger's physics-based platform, is now in Phase 3 trials through Takeda for inflammatory and autoimmune diseases.
The TYK2 programme's commercial track record is genuinely category-defining: BMS acquired the original Nimbus TYK2 programme for up to $6B in 2022, and Eli Lilly's April 2026 announcement of a $2.3B acquisition of Ajax Therapeutics (another Schrödinger co-founded company in which Schrödinger held ~6% equity) represents the latest in a sequence of multibillion-dollar exits validating the platform.
For a royalty market readership, Schrödinger's 15 royalty-eligible partner programmes and ~$5B in disclosed potential milestone payments make it the most royalty-relevant AI-drug-discovery story in absolute scale.
Insilico holds the most clinically advanced fully-AI-generated drug.
Rentosertib, an Insilico-discovered and Insilico-designed TNIK inhibitor for IPF, was published in Nature Medicine in June 2025 with a +98.4 mL FVC improvement at 60 mg QD versus −20.3 mL decline on placebo over 12 weeks — the first peer-reviewed Phase 2a proof-of-concept for a drug where both the target (TNIK) and the molecular structure were AI-discovered.
The April 28, 2026 IND clearance on the rentosertib inhalation formulation is Insilico's 13th IND from its Pharma.AI-driven pipeline.
Combined with the near-$120M January 2026 Qilu Pharmaceutical cardiometabolic partnership and prior collaborations with Eli Lilly, Sanofi, Fosun, and others, Insilico has the most coherent end-to-end track record in the sector.
The Recursion-Exscientia combined entity has had a difficult 2025-2026.
The merger closed November 20, 2024 and created a vertically integrated AI drug discovery platform with over 10 clinical and preclinical programmes and a partner stack with Bayer, Roche, and Sanofi.
By May 2025, however, Recursion halted four pipeline programmes, including REC-3964 in C. diff infection (citing competitive crowding and low recurrence rates in standard care), and REC-4209 in IPF, narrowing the pipeline to six active programmes focused on cancer and rare disease.
REC-4881, the MEK1/2 inhibitor for familial adenomatous polyposis, is now the lead Phase 2 asset.
Q1 2026 results reported strong Phase 2 efficacy signals on REC-4881 (43% median polyp burden reduction at week 13, n=6) and FDA engagement to define a potential registrational path, with update expected in 2H 2026.
BenevolentAI delisted from Euronext Amsterdam on March 13, 2025.
The company merged with Osaka Holdings S.à r.l., transitioned to a private company structure, and reshaped its workforce to extend cash runway into 2027.
Co-founder Kenneth Mulvany returned as Executive Chairman in October 2024 and led the strategic overhaul.
The company's stated direction is a return to its "TechBio" mission with partnered drug candidates earlier in development to reduce balance-sheet risk.
For purposes of the AI-drug-discovery peer comparison, BenevolentAI has effectively exited the publicly tracked cohort.
Innovo's positioning relative to this cohort is precisely calibrated.
DeepZema® is not competing on generative-chemistry-novelty.
It explicitly disavows generative reinforcement learning in favour of classical de novo design plus AI scoring.
Instead it competes on capital efficiency: an AI-augmented computational chemistry stack that a small Korean startup can run, applied to mechanistically novel small-molecule targets sourced from Korean academic and biopharma networks, optimised in-house, and tested in Korea / U.S. early-clinical programmes with KDDF support.
The cumulative equity raised (~$33.9M) is roughly one twelfth of Insilico's ($400M+ cumulative) and one thirtieth of the Recursion-Exscientia combined entity ($1B+ total funding).
The pipeline shape — INV-001 Phase 3 IND submitted, INV-101 Phase 2 ready with U.S. FDA IND cleared, INV-008 licensed to a major Korean pharma — is not implausibly behind on a capital-adjusted basis.
The platform-validation question for Innovo is the same as for the entire AI-drug-discovery cohort: does the platform produce multiple externally validated programmes within a short cycle time?
Schrödinger's answer is 15 royalty-eligible partner programmes, ~$5B in potential milestone payments, and one Phase 3 asset (zasocitinib).
Insilico's answer is 22 development/preclinical candidates nominated since 2021, 13 INDs cleared, 1 Phase 2a publication.
Innovo's answer as of May 13, 2026 is one externally validated programme (INV-008 / Daewoong), one Phase 2-ready asset with cleared U.S. IND (INV-101), one Phase 3-IND-submitted Korean dermatology asset (INV-001), and seven preclinical / lead-optimisation programmes.
The trajectory matters more than the absolute number.
A successful INV-101 Phase 2 readout in 2027 followed by a second out-licensing transaction in 2027–2028 would establish the platform at a different tier.
The IP footprint supports the platform claim.
Per the Innovo IP page, the company holds 86 registered patents and 25 pending applications, with PCT filings on the core composition-of-matter chemistry for the lead programmes.
The relevant Korean / PCT filings include:
- Heteroarylamidopyridinol derivatives (KR 10-2426921, WO 2021/060890) for autoimmune disease, almost certainly the INV-101 PYGL scaffold
- Benzbromarone-derived keloid / hypertrophic scar composition (KR 10-2404883, WO 2022/114881), INV-001
- Benzofuranyl hydroxyphenyl methanone derivatives (KR 10-2684807, WO 2023/059121), plausibly INV-008 or adjacent 15-PGDH chemistry
- Benzofuranyl hydroxyphenyl methanone oxime derivatives (KR 10-2782945, WO 2023/229099)
- Isoindolinone caspase inhibitors (KR 10-2670554, WO 2023/132606)
- Novel heterocyclic compounds (KR 10-2727682, WO 2024/154979)
- Novel pyrazole derivatives (KR 10-2791027, WO 2025/009852)
All seven registered PCT filings are first-party Innovo inventions with no obvious upstream academic or external licensor attribution in the public record.
The downstream royalty stack on the lead programmes therefore has, to a first approximation, no upstream third-party royalty layer to model.
INV-008: The Daewoong Deal, the Royalty Stack, and the Underlying Asset
Deal structure
The May 13, 2026 joint press release and the parallel Korean Exchange disclosure filed by Daewoong on May 12 establish the contract structure on INV-008:
| Term | Detail |
|---|---|
| Asset | INV-008, oral small-molecule 15-PGDH inhibitor |
| Indication | Inflammatory bowel disease (UC + Crohn's), with adjacency expansion rights |
| Territory | Worldwide, exclusive |
| Rights to Daewoong | Development, manufacturing, commercialisation |
| Structure | Joint development; Innovo retains discovery and early non-clinical research; Daewoong leads clinical and commercial |
| Upfront | KRW 6.5B (~$4.4M), non-refundable |
| Development milestones | up to KRW 19.0B (~$12.8M) |
| Regulatory milestones | up to KRW 207.0B (~$139M) |
| Sales milestones | up to KRW 430.0B (~$289M) |
| Total deal value | up to KRW 662.5B (~$445M) |
| Running royalty | Not publicly disclosed in current filings |
Royalty stack on INV-008
Three observations on the royalty stack as a structural matter.
No running royalty has been publicly disclosed.
The Korea Exchange disclosure breaks the milestone ladder into development / regulatory / sales tranches, with sales milestones (KRW 430B, ~$289M) representing roughly 65% of the total deal cap.
Sales milestones are tiered cumulative-revenue trigger payments, structurally different from a running royalty rate applied to net sales.
The current public disclosure does not specify whether a running royalty layer exists on top of the sales-milestone ladder.
In Korean licensing practice, sales milestones and running royalties frequently co-exist, but the running-royalty rate is usually not disclosed for confidentiality reasons.
The deal contract itself is not public.
For purposes of royalty market analysis, the working assumption should be that a running royalty layer exists but is not publicly disclosed, with the sales-milestone ladder representing a separate cumulative-threshold-based payment stream.
The total cash flow back to Innovo from a successful INV-008 commercial launch is therefore the milestone ladder plus any undisclosed running royalty.
The royalty stack is otherwise clean.
No upstream academic or foundation licensor is on the INV-008 chemistry per the Innovo IP page and the relevant PCT filings (benzofuranyl hydroxyphenyl methanone derivatives, WO 2023/059121 and adjacent).
KDDF funding on INV-008 since June 2023 is structured as grant / cost reimbursement with no royalty pull-through.
The discovery platform (DeepZema®) is in-house and not licensed in from any third party.
There is no manufacturing or cell-line royalty layer because the asset is a small molecule, oral.
The downstream royalty stack on INV-008 net sales is therefore, from Innovo's perspective, a single-licensor structure with no upstream encumbrance.
The royalty potential for Innovo is bounded by the milestone ladder, plus any undisclosed running royalty, minus any onward Daewoong sub-licensing economics governed by the underlying Innovo-Daewoong contract.
Daewoong's framing in press coverage emphasises that it intends to "lead global commercialisation directly," suggesting the company sees this as a strategic asset to develop and commercialise in-house rather than a near-term sub-licensing candidate.
If Daewoong does eventually out-licence INV-008 to a U.S. or EU player for global Phase 3 and commercialisation (a common pattern for Korean pharma in-licensors lacking U.S. / EU commercial scale), the economics of that downstream transaction are governed by the Innovo-Daewoong contract, which is not public.
The asset itself
INV-008 is positioned as a first-in-class oral 15-PGDH inhibitor for inflammatory bowel disease.
15-PGDH (15-hydroxyprostaglandin dehydrogenase) is the principal enzyme degrading prostaglandin E2 (PGE2), an endogenous regulator of gastrointestinal homeostasis with documented roles in epithelial barrier integrity, mucosal repair, and resolution of inflammation.
15-PGDH is transcriptionally upregulated in the inflamed mucosa of IBD patients, with PGE-MUM (a marker of systemic PGE2 turnover) correlating with disease activity in both ulcerative colitis and Crohn's disease.
The therapeutic logic is differentiated from incumbent IBD mechanisms.
Current standards of care (anti-TNF, anti-integrin, anti-IL-23, JAK inhibitors, S1P modulators) all act primarily on the inflammatory cascade.
A 15-PGDH inhibitor acts on tissue repair: by inhibiting the enzyme that degrades PGE2, it restores physiological PGE2 levels in the inflamed mucosa, supporting epithelial regeneration alongside reduction in inflammatory tone.
The mechanism is closer in spirit to mucosal healing as a therapeutic strategy than to anti-inflammation per se.
INV-008 is not the only 15-PGDH programme in IBD.
Epirium Bio presented translational data on its oral 15-PGDH inhibitors MF-300 (Phase 2-ready, with reported endoscopic improvement indicative of mucosal healing in preclinical efficacy readouts) and MF-1305 at Digestive Disease Week 2026 in Chicago, May 2-5.
MF-300 is materially ahead of INV-008 on development timeline.
The competitive context matters: INV-008 will need to demonstrate either a differentiated chemical scaffold, a superior PK / safety profile, or an indication-defining mucosal-healing signal in early human studies to maintain optionality against MF-300 once both are in Phase 2.
The global IBD market is large and growing.
Per Fortune Business Insights data cited in Korean press coverage of the deal, the global IBD therapeutics market was approximately $29.57 billion in 2025 and is projected to reach $41.64 billion by 2034.
INV-101: The Unpartnered Phase 2-Ready Asset
INV-101 is the asset to watch for the next major royalty-relevant event in Innovo's pipeline.
It is a first-in-class oral small-molecule glycogen phosphorylase (PYGL) inhibitor for ulcerative colitis, with U.S. FDA IND clearance received in 2025 and global Phase 2 initiation planned for 1H 2026.
The mechanism is structurally novel: rather than suppressing immune signalling, INV-101 disrupts the metabolic reprogramming of pro-inflammatory immune cells by inhibiting PYGL, the enzyme controlling glycogen breakdown in hyperactivated immune cells.
The Phase 1 study — randomised, double-blind, placebo-controlled, single ascending dose / multiple ascending dose plus food effect, 48 healthy adult subjects in the U.S. — completed in May 2025 with no SAEs or DLTs.
Pharmacokinetics were supportive of once-daily oral dosing.
The Nature publication trail on PYGL expression in UC patients provides mechanistic grounding: PYGL activity is significantly elevated in UC patient mucosa versus healthy controls.
Royalty stack on INV-101:
| Layer | Detail |
|---|---|
| Composition of matter | Owned outright by Innovo; primary patent likely WO 2021/060890 (heteroarylamidopyridinol derivatives for autoimmune disease) |
| Upstream academic / foundation licence | None publicly disclosed |
| KDDF support | Cost-reimbursement grant for Phase 1 with two additional years earmarked; no royalty pull-through |
| Manufacturing royalty | None applicable (oral small molecule) |
| Synthetic royalty / debt | None |
| Current out-licence partner | None, unpartnered as of May 13, 2026 |
INV-101 is the cleanest royalty-financeable asset in the Innovo pipeline.
Composition of matter is in-house, no upstream royalty layer, no current out-licence partner, U.S. IND cleared, Phase 1 safety / PK profile supportive of once-daily oral dosing.
If the Phase 2 readout in 2027 is positive, the asset becomes the obvious anchor for Innovo's next licensing transaction.
The competitive bar for INV-101 in UC is high.
Vedolizumab, ustekinumab, Skyrizi (risankizumab), guselkumab (Tremfya), JAK inhibitors, S1P modulators, and mirikizumab all sit ahead in the treatment algorithm.
INV-101 enters as a mechanistically novel first-in-class candidate without a comparator within its class.
This is both an opportunity (no direct competitive comparator data exists to set the bar) and a development risk (the immuno-metabolic UC thesis is unvalidated in patients).
INV-001: The Phase 3-IND-Stage Topical Scar Asset
INV-001 is a topical small-molecule HSP47 inhibitor for hypertrophic scar and keloid.
The Phase 2 trial, conducted across four Korean hospitals including Severance, randomised 77 patients post-thyroidectomy to twice-daily INV-001 application (0.2% low dose / 2% high dose / placebo) for 12 weeks with POSAS scar assessment as the primary endpoint.
The per-protocol high-dose arm showed a 24.5% scar reduction at week 12 with statistical significance versus placebo (p<0.05, ANCOVA) and no serious adverse events.
The May 13 Daewoong release confirmed an INV-001 Phase 3 IND application has been submitted.
Trial design, primary endpoint, and territories have not yet been disclosed publicly.
Royalty stack on INV-001:
| Layer | Detail |
|---|---|
| Composition of matter | Owned outright by Innovo; primary patent KR 10-2404883, WO 2022/114881 (benzbromarone-derived scar treatment composition) |
| Mechanistic chemistry | First-in-class HSP47 inhibitor / degrader scaffold per JID 2023 and AAD 2023 posters; benzbromarone is an old uricosuric drug whose patent has expired, so the underlying scaffold is unencumbered |
| KDDF support | Various stages |
| Manufacturing royalty | None applicable (topical small molecule formulation) |
| Synthetic royalty / debt | None |
| Current out-licence partner | None, unpartnered as of May 13, 2026 |
The royalty potential on INV-001 depends materially on the Phase 3 design and the eventual commercial positioning.
Korean topical Rx scar treatments addressable through a pharmacy / dermatology channel can support royalty-financeable economics in the $50–200M annual peak-sales range in a domestic-only registration.
A successful global Phase 3 supporting a U.S. / EU Rx scar registration would expand the addressable population materially.
The asset is presently unpartnered.
The obvious natural acquirer profile is a Korean or global derm-focused specialty pharma: Galderma, Almirall, Bausch Health, Mayne Pharma, or Korean dermatology players.
The Full Pipeline
The pipeline as of May 2026 spans ten disclosed programmes across four therapeutic areas.
| Programme | Indication | Target / mechanism | Stage | Partner |
|---|---|---|---|---|
| INV-001 | Hypertrophic scar / keloid | HSP47 inhibitor (topical) | Phase 2 complete; Phase 3 IND submitted | None |
| INV-002 | Liver fibrosis (expansion to lung, kidney, skin) | Undisclosed; collagen biosynthesis in hepatic stellate cells (oral) | Candidate | None |
| INV-004 | Osteoarthritis | NLRP3/NLRP1 inflammasome (intra-articular) | Preclinical | None |
| INV-005 | IPF | TGF-β pathway enzymes (oral) | Lead optimisation | KDDF-supported |
| INV-006 | Androgenic alopecia | Dual mechanism (topical) | Hit-to-lead | KDDF-supported |
| INV-007 | Severe asthma / cystic fibrosis | Neutrophil function (inhaled) | Hit-to-lead | None |
| INV-008 | IBD | 15-PGDH inhibitor (oral) | Preclinical / IND-enabling | Daewoong (May 13, 2026) |
| INV-009 | Blood cancer / solid tumor (monotherapy) | Cancer metabolism enzymes (oral) | Lead optimisation | None |
| INV-010 | Blood cancer / solid tumor (ADC) | Same scaffold, ADC payload (injection) | Lead optimisation | None |
| INV-101 | Ulcerative colitis | PYGL inhibitor (oral) | Phase 2 ready, U.S. IND cleared | None |
Of ten programmes:
- One is licensed (INV-008 / Daewoong)
- One is Phase 2 ready and unpartnered (INV-101)
- One has Phase 2 data and Phase 3 IND submitted (INV-001)
- Seven sit at preclinical / hit-to-lead / lead-optimisation
The platform-throughput thesis on DeepZema® currently has one externally validated programme.
INV-101's upcoming Phase 2 readout is the next live data point.
A successful INV-101 Phase 2 readout, followed by an INV-001 Phase 3 positive readout in 2028–2029 and a second out-licensing transaction in 2027–2028, would establish DeepZema® at a different tier of platform validation.
Asset-by-Asset Royalty Potential Summary
| Asset | Royalty stack | Out-licensing status | Royalty-financeable horizon |
|---|---|---|---|
| INV-008 (15-PGDH, IBD) | Clean: in-house COM, no upstream layer, no manufacturing royalty | Licensed to Daewoong worldwide for IBD + adjacencies; ~$445M total milestone cap; running royalty not publicly disclosed | Royalty-relevant cash flow tied to Daewoong's clinical and regulatory execution; sales-milestone-heavy structure (KRW 430B sales milestones = 65% of total); first material payments contingent on Phase 1 / 2 progression 2026-2028 |
| INV-101 (PYGL, UC) | Clean: in-house COM, no upstream layer, no manufacturing royalty, no current partner | Unpartnered; Phase 2 initiation 1H 2026, U.S. FDA IND cleared | The most royalty-financeable forward asset in the Innovo portfolio; partnering window post-positive Phase 2 readout in 2027-2028; first-in-class oral PYGL mechanism with no direct competitive comparator |
| INV-001 (HSP47, scar) | Clean: in-house COM (benzbromarone scaffold expired), no upstream layer | Unpartnered; Phase 2 validated (24.5% reduction, p<0.05); Phase 3 IND submitted | Royalty-financeability depends on Phase 3 design and territory (global Rx vs Korea-only); natural partner profile is derm-focused specialty pharma; 2027-2029 transaction window |
| INV-002 through INV-010 | Clean stack across all programmes; in-house chemistry | Unpartnered; preclinical / lead optimisation | 2028+ |
The portfolio-level observation: all three lead assets carry clean royalty stacks with no upstream encumbrance.
This is a function of Innovo's in-house discovery model and the KDDF grant structure, which does not pull through royalties on commercialised products.
The stack is structurally distinct from Korean academic-origin biotechs that frequently carry university or foundation royalty layers on their lead programmes, and from in-licensed-asset Korean biotechs that carry origin-company royalty obligations.
Red Team vs Blue Team Analysis
Risk Analysis (Red Team)
INV-008 is pre-IND.
The Daewoong deal is on a preclinical asset.
The 15-PGDH IBD thesis is mechanistically interesting and supported by genetic, animal-model, and human-correlation data, but no 15-PGDH inhibitor has been clinically validated in IBD to date.
Epirium's MF-300 has reported preclinical mucosal-healing data but is itself only Phase 2-ready as of May 2026.
The mechanism class as a whole has not delivered a positive randomised Phase 2 in IBD.
INV-008 carries indication-and-class development risk in addition to compound-specific risk.
INV-008 milestone structure is sales-milestone-heavy.
Of the KRW 662.5B total deal cap, KRW 430B (~65%) sits in sales milestones contingent on commercial launch and cumulative-revenue thresholds.
Sales milestones in preclinical-asset Korean licensing deals frequently go unpaid because the asset fails to reach commercial stage.
The disclosed cap is a maximum, not an expected value.
A risk-adjusted probability-weighted modelled value of INV-008 to Innovo, applying typical preclinical-to-commercial success rates (~6–10% in IBD), would yield a much smaller figure than the headline $445M suggests.
No publicly disclosed running royalty on INV-008.
The Korea Exchange disclosure breaks the deal into upfront / development milestones / regulatory milestones / sales milestones, with no public running royalty rate.
A pure-milestone deal structure (or a deal with a low single-digit running royalty) is materially less royalty-financeable than a tiered-royalty structure with disclosed mid-to-high single-digit rates.
Competitive risk on 15-PGDH IBD is real.
Epirium Bio's MF-300 is materially ahead on development timeline.
Additional 15-PGDH chemistry exists in academic and industrial labs (the Case Western SW033291 scaffold is one published precedent).
If MF-300 reads out positively in Phase 2 before INV-008 begins Phase 2, the competitive landscape compresses materially.
INV-101 PYGL mechanism is differentiated but unvalidated in UC patients.
Glycogen phosphorylase inhibition as an immune-metabolic strategy in UC is genuinely first-in-class, supported by Phase 1 safety / PK data but unvalidated in patients.
A first-in-class Phase 2 in UC against a high competitive bar (mirikizumab, risankizumab, guselkumab, S1P modulators) needs to show either a differentiated safety profile, a differentiated efficacy in a defined sub-population, or both.
None of those are yet established.
Daewoong is a strong Korean licensee but not a global commercial pharma.
Daewoong has Korean commercial scale and growing APAC presence but is not Roche, Pfizer, or AbbVie.
The press coverage indicates Daewoong intends to "lead global commercialisation" directly, which adds execution risk on a company without prior global Rx launch experience in a major-market IBD setting.
Platform-throughput claim trails Schrödinger and Insilico on absolute scale.
Schrödinger has 15 royalty-eligible partner programmes and one Phase 3 asset (zasocitinib via Takeda) globally — the most clinically advanced AI-assisted drug in the world.
Insilico has 13 INDs cleared, 22 development/preclinical candidates nominated since 2021, and a published Phase 2a clinical PoC (rentosertib).
Innovo has one externally validated programme as of May 2026.
The capital-efficiency framing is real, but the validation gap is also real.
INV-001 Phase 3 design and territory are undisclosed.
The May 13 release confirmed an INV-001 Phase 3 IND has been submitted but disclosed no trial design or primary endpoint.
The asset's commercial value depends materially on whether Phase 3 supports a global Rx scar indication or only a Korean / Asian regulatory path.
A Korea-only registration trajectory would significantly compress the royalty-financeability of the asset.
Capital structure is private and information-limited.
Innovo does not publish audited financials.
PitchBook and Crunchbase triangulation provides ~$33.9M cumulative equity but no current cash runway disclosure, burn rate disclosure, or pipeline-cost disclosure.
| Risk Category | Key Concern |
|---|---|
| INV-008 development stage | Pre-IND; no 15-PGDH inhibitor has cleared Phase 2 in IBD |
| INV-008 milestone structure | 65% of deal cap in sales milestones; running royalty undisclosed |
| 15-PGDH competition | Epirium's MF-300 is Phase 2 ready; additional academic / industrial chemotypes exist |
| INV-101 PYGL mechanism | First-in-class but unvalidated in UC patients; high competitive bar |
| Daewoong licensee profile | Strong Korean pharma but not a global commercial pharma |
| Platform scale vs peers | Schrödinger has Phase 3 asset; Insilico has Phase 2a published PoC; Innovo trails on absolute scale |
| INV-001 Phase 3 design | Trial design / territory / endpoint undisclosed |
| Private-company information | No audited financials; cash runway, burn, pipeline costs all undisclosed |
Opportunities and Mitigants (Blue Team)
All three lead assets carry clean royalty stacks.
INV-008, INV-101, and INV-001 are all built on Innovo-owned composition-of-matter with no upstream academic, foundation, or platform-IP royalty layer.
KDDF grants do not pull through royalties.
There is no manufacturing royalty layer because all assets are small molecules.
This is structurally distinct from the licensing ledger at most academic-origin Korean biotechs.
INV-101 is the highest-value forward asset.
Unpartnered Phase 2-ready first-in-class oral PYGL inhibitor in UC, with U.S. FDA IND cleared, Phase 1 safety / PK supportive of once-daily oral dosing, and a clean royalty stack.
A successful Phase 2 readout in 2027 creates immediate licensing leverage with global pharma counterparties in a market where IBD is one of the most actively partnered therapeutic areas.
The Daewoong INV-008 deal validates DeepZema® externally for the first time.
A KRW 662.5B / ~$445M total-deal-value transaction on a preclinical asset with worldwide exclusive rights to a major Korean pharma is the first externally validated DeepZema®-originated programme.
For the platform-validation thesis, one validated programme is the threshold below which the platform is a thesis and above which it is a developing track record.
The next datapoint — INV-101 Phase 2 or a second out-licensing — moves the needle on that track record.
INV-001 is the only Korean topical scar asset at Phase 3 IND stage.
The 2024 Phase 2 readout (24.5% scar reduction at week 12, statistically significant vs placebo) is a real datapoint.
A successful Phase 3 supports a global Rx scar registration path with no obvious direct comparator in the topical small-molecule space.
KDDF support across multiple programmes provides non-dilutive runway and credibility.
The KDDF grants on INV-001, INV-005, INV-006, INV-008, and INV-101 represent a meaningful non-dilutive funding stack and signal Korean government-level scientific endorsement.
The structural feature here — KDDF grants are cost-reimbursement without royalty pull-through — leaves Innovo's downstream royalty stack clean across the funded programmes.
Capital efficiency relative to AI-drug-discovery peers is real.
Innovo has produced one externally validated programme (INV-008 / Daewoong), one Phase 2-ready asset with U.S. IND cleared (INV-101), and one Phase 2-validated and Phase 3-IND-stage asset (INV-001) on ~$33.9M cumulative equity.
The peer cohort comparison as of May 2026 is striking: Insilico has raised $400M+ cumulative, Recursion-Exscientia combined has $1B+ in total funding, Schrödinger reported $406M in Q1 2026 cash alone.
BenevolentAI is now private and significantly restructured.
Innovo's capital-adjusted output story is competitive within the cohort, even if absolute scale lags.
The IP footprint supports the platform-throughput claim.
Eighty-six registered patents and twenty-five pending applications, with PCT filings on the core composition-of-matter chemistry for the lead programmes.
The breadth of registered chemistry is substantial for a company of Innovo's capital base, and the PCT filings provide global IP protection.
Post-Daewoong capital position is materially improved.
Combined ~$4.4M upfront cash plus a Korean-pharma-strategic-partner credential makes Innovo a more credible candidate for a Series B / pre-IPO round in 2026-2027.
KOSDAQ listing is a plausible 2027-2028 path.
| Opportunity | Observation |
|---|---|
| Clean royalty stacks on all three lead assets | In-house COM, no upstream layer, no KDDF royalty, no manufacturing royalty |
| INV-101 unpartnered Phase 2-ready | First-in-class oral PYGL UC asset; cleanest royalty-financeable asset in portfolio |
| INV-008 Daewoong validation | First externally validated DeepZema®-originated programme; worldwide rights to credentialed Korean pharma |
| INV-001 Phase 3 IND | Only Korean topical scar asset at Phase 3 stage |
| KDDF non-dilutive support | Multi-programme grant funding without royalty pull-through |
| Capital efficiency vs AI-drug-discovery peers | Three clinical or Phase 3-IND assets on ~$33.9M cumulative equity |
| IP footprint | 86 registered patents, 25 pending; PCT coverage on lead programme chemistry |
| Post-Daewoong capital position | Strengthened pathway to Series B / pre-IPO / KOSDAQ |
Scenario Analysis
Base case.
INV-101 Phase 2 initiates on schedule in 1H 2026 with topline data plausibly available in late 2027 / 2028.
INV-008 advances under Daewoong sponsorship into Phase 1 in 2026-2027, triggering the first KRW 19B development-milestone tranche.
INV-001 Phase 3 trial design is disclosed in 2H 2026 with trial initiation in late 2026 / early 2027.
Innovo raises a Series B / pre-IPO Korean round in 2027 at a stepped-up valuation supported by the Daewoong deal credential.
Better-than-expected.
INV-101 Phase 2 reads out positively on the primary endpoint in 2027, triggering global pharma licensing interest and a transaction comparable in scale (or larger) to the Daewoong INV-008 deal but with a global commercial pharma counterparty and a fully disclosed royalty structure.
Daewoong successfully advances INV-008 through Phase 2 in 2027-2028, triggering substantial regulatory milestone payments.
INV-001 Phase 3 reads out positively in 2028 on a global trial design.
KOSDAQ listing in 2028 at a meaningfully expanded valuation.
DeepZema® is independently validated by a second externally validated programme.
Worse-than-expected.
INV-101 Phase 2 reads out negatively or borderline on the primary endpoint, undermining the PYGL immuno-metabolic thesis.
Epirium's MF-300 Phase 2 reads out positively before INV-008 enters Phase 2, materially compressing the competitive position for INV-008.
INV-001 Phase 3 design lands in a Korea-only registration trajectory, capping the asset's commercial value.
The DeepZema® platform claim remains at single-programme validation.
Capital raising in 2027-2028 becomes more difficult.
Conclusion
Innovo Therapeutics is, in the narrow sense, a Korean private-stage small-molecule platform biotech.
The portfolio includes one externally validated programme (INV-008 / Daewoong, May 13, 2026), one Phase 2-ready unpartnered asset (INV-101), one Phase 2-validated and Phase 3-IND-stage topical asset (INV-001), and seven preclinical programmes.
The KRW 662.5B / ~$445M Daewoong licensing transaction is the company's inaugural large licensing event and the first externally validated DeepZema®-originated programme.
For a royalty market readership, the more interesting facts are four.
First, all three lead assets — INV-008, INV-101, INV-001 — carry clean royalty stacks with no upstream academic, foundation, platform-IP, or manufacturing royalty layer.
This is a function of Innovo's in-house discovery model and the structure of KDDF grant support.
Second, INV-101 is an unpartnered Phase 2-ready first-in-class oral PYGL inhibitor in UC with cleared U.S. FDA IND.
It is the cleanest royalty-financeable asset in the portfolio, with a partnering window opening on positive Phase 2 data in 2027–2028.
Third, the INV-008 / Daewoong deal structure concentrates 65% of headline deal value in sales-milestone payments contingent on commercial launch.
The risk-adjusted modelled value of the deal to Innovo is materially below the $445M headline, and no running royalty has been publicly disclosed.
Fourth, the DeepZema® platform's positioning relative to the AI-drug-discovery peer cohort as of May 2026 is a deliberate capital-efficiency choice.
Innovo explicitly disavows generative-reinforcement-learning chemistry in favour of AI-augmented classical computational chemistry sized to a small-startup capital base.
This has produced competitive capital-adjusted output to date.
It has not yet matched either the clinical-stage absolute scale of Schrödinger (Phase 3 zasocitinib, 15 royalty-eligible partner programmes, ~$5B in disclosed milestone potential) or the published Phase 2a clinical proof-of-concept set by Insilico's rentosertib in IPF.
The platform-throughput thesis on DeepZema® has one externally validated data point as of today.
A second externally validated programme — most plausibly INV-101 partnering after Phase 2 — would materially strengthen the claim.
It would also be the event that converts the cleanest unencumbered asset in the portfolio into a royalty-financeable cash flow.
For readers tracking Asian preclinical-to-Phase 2 licensing flow and the emerging royalty-financeability of AI-drug-discovery platform output more broadly, Innovo's Daewoong transaction is worth examining for the deal-cap composition as much as for the headline number.
The sales-milestone-heavy structure is the precedent, not the cash.
Covered as Day 3 (Wednesday, May 13) of The Weekly Term Sheet 2026-W19 — Innovo Therapeutics / Daewoong Pharmaceutical INV-008 Licensing Agreement (KRW 662.5B total deal value; worldwide exclusive rights; sales-milestone-heavy structure; running royalty undisclosed) — the structural composition of the milestone ladder is the kind of disclosure pattern we expect to see more frequently in Korean and APAC preclinical out-licensing flow through the remainder of 2026.
All information in this article is derived from publicly available sources including company press releases, Korea Exchange disclosures, regulatory filings, investor databases, peer-reviewed publications, and financial news reporting. Information may have changed since publication. Innovo Therapeutics is a private company and does not publish audited financial statements; financial estimates are based on third-party databases and press coverage. This content is for informational purposes only and does not constitute investment, legal, or financial advice. The author is not a lawyer or financial adviser.